DELPHI expert consensus-derived factors influencing the early use of monoclonal high-efficacy therapies in treatment-naïve patients with relapsing-remitting multiple sclerosis.
Bourre B, Guerrier O, Ayrignac X, Suchet L, de Seze J, Masmoudi I, Ricigliano VAG, Vermersch P, Ciron J, CAReSEP working group
J Neurol. 2026 Oct 22; 273(11). PMID: 42911241.Abstract
